2001, Licensing and Protein Expression

Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions

The Pharma Data

JANUARY 13, 2021

CD40-ligand is a protein expressed on the surface of activated T lymphocytes that mediates T cell helper function. Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Structure.

Pharmaceuticals

Pharmaceuticals Small Molecule Vaccine Protein Expression

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

NOVEMBER 9, 2023

Peter O’Callaghan, PhD, Head of Expression System Sciences, Biologics and Licensing, Lonza, on: ‘Solve bispecific heavy-light chain mispairing with bYlok technology’. Sara Majocchi, PhD, Discovery Program Leader, Light Chain Bioscience – Novimmune SA, on: ‘Bispecific antibody mediated, PD-L1-dependant, CD28 co-stimulation’.

Engineering

Engineering Therapies Protein Production Science

Drug Discovery Digest

Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions

What to expect from PEGS Europe 2023: Day 2

Stay Connected